01.10.2011 • News • Momenta Pharmaceuticals • Watson Pharmaceuticals

Momenta Files for Injunction Against Amphastar, Watson and Int'l Medical Systems

Momenta Pharmaceuticals announced that it has filed a request for a temporary restraining order and preliminary injunction to prevent Amphastar Pharmaceuticals, Watson Pharmaceuticals and International Medical Systems from launching their enoxaparin sodium product in the United States.

On September 21, 2011 Momenta announced that it had sued Amphastar, Watson, and International Medical Systems in the United States District Court for the District of Massachusetts for infringement of two Momenta patents.

The patents cover the company's methods of producing enoxaparin sodium.

Virtual Event

CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.